Clinical Trials: Phases, Endpoints and Interpreting Failure
A trial result depends on its patients, comparator, endpoint and follow-up. This topic explains trial phases, limits on endpoint claims, and how to investigate an efficacy failure without assuming its cause.
What a learner can do afterwards
- Identify phase 1 safety and dosing aims, and explain why phase 3 findings do not automatically apply to unstudied populations.
- Distinguish a surrogate endpoint from a clinical one and say what each can support
- Explain how an efficacy failure can arise from target biology, exposure, patient selection or trial design without proving one cause.
1 · Read
Phase 1 studies early safety, tolerability, dose and how the body handles a drug in small groups. Participants may be healthy volunteers or patients, depending on the treatment and disease. Phase 2 studies preliminary efficacy, dosing and safety in patients with the condition. Neither phase establishes safety for everyone or guarantees success in later studies.
Phase 3 usually compares treatment with an appropriate control in larger patient groups to confirm efficacy and assess harms. Controls can include standard care or placebo when justified. Phase 4 studies approved treatments in use. Phases can overlap or combine. Results concern the studied population, disease, dose, comparator and follow-up; adult results alone do not establish benefit in children.
Random assignment reduces bias from choosing who receives treatment. It balances measured and unmeasured factors on average, not exactly in every trial. Concealing upcoming assignments prevents recruiters from steering enrollment. Blinding hides allocation from participants, care teams or outcome assessors where feasible. It can reduce expectation-related bias in care, reporting and scoring. These methods are not restricted to one phase.
An endpoint is a prespecified outcome measured at a stated time. Clinical endpoints measure how patients feel, function or survive. A surrogate is a marker used to predict clinical benefit. A marker change alone does not establish benefit. Its interpretation needs evidence that treatment effects on the marker predict clinical effects in that setting. A continuous blood-marker change is not a risk; a risk ratio needs a defined event.
Risk is the fraction of participants with at least one defined event during a fixed follow-up. Relative risk = treatment risk / control risk, if control risk is nonzero. With 8 of 100 treated patients and 20 of 100 controls having a stroke by one year, the ratio is 0.08 / 0.20 = 0.4. This describes that event over that year. An interval expresses estimation uncertainty. Check missing outcomes and harms too.
Efficacy is explored in phase 2 and tested further in phase 3. Lack of efficacy can reflect target biology, inadequate exposure, dose, patient selection or trial design. Validation from the discovery stop guides these checks but cannot guarantee patient benefit. A null result alone does not identify its cause. Comparing failure across phases needs a defined set of programs and the number entering each phase.
Ethics review examines scientific value, fair recruitment, privacy and risks relative to possible benefits and the value of the knowledge. Valid consent explains material risks and alternatives and supports a voluntary decision. Refusal must not be punished by loss of usual care. Vulnerability calls for suitable safeguards, not automatic exclusion. A novel endpoint does not excuse coercion or missing risk information.
Match claims to the trial's patients, design and endpoint. Randomization reduces bias. Marker changes and efficacy failures need careful interpretation.
Readings and flashcards written for this dataset. Video: "Impact of mass on orbital speed | Study design | AP Statistics | Khan Academy", by Khan Academy.
More to read
Specify the trial question
A candidate that acts on a target still needs testing in people. Before reading its results, identify the eligible patients, treatment, comparison, outcome and follow-up. These details set the boundaries of the question.
Consider a hypothetical trial of an arthritis drug. Adults receive either the new drug plus usual care or placebo plus usual care. Walking function is assessed at twelve weeks. This comparison asks whether adding the drug improves that outcome in those adults over that period. It does not directly test survival or treatment in children.
Trial phases describe usual research aims. Phase 1 examines early safety, tolerability, dosing and how the body handles the drug. Depending on the treatment, participants may be healthy volunteers or patients. Phase 2 explores efficacy and safety in patients with the condition. Phase 3 usually compares efficacy and harms in larger patient groups. Phase 4 studies treatments after approval.
A program can combine phases. Calling a study phase 3 does not make its patients representative of every population or its endpoint a direct measure of clinical benefit.
Separate assignment from assessment
Suppose clinicians tend to give a new treatment to patients with more severe illness. A later difference in outcomes could reflect the treatment, the starting severity, or both. Comparing the groups without addressing that selection can mislead.
Random assignment separates treatment allocation from those choices. It balances prognostic factors on average across repeated assignments, including factors researchers did not measure. A particular trial can still have chance imbalances. Keeping the next assignment hidden also prevents recruiters from selecting participants to obtain a preferred treatment.
Blinding addresses another source of bias. Treatment knowledge can affect reported symptoms, clinical decisions and outcome scoring. Keeping allocation hidden from participants, care teams or assessors can reduce these influences. Some treatments cannot be hidden, so the protocol should explain who is blinded and how outcomes are assessed.
Random assignment does not repair every study problem. Missing outcomes can still bias a comparison. Assignment also differs from sampling: allocating enrolled participants by chance does not make them a random sample of everyone who might use the treatment.
Check whether participation is informed and voluntary
Consent is a process for supporting a person's decision about research. Explain the purpose, procedures, material risks, possible benefits and alternatives. An uncertain treatment must not be presented as guaranteed help.
Imagine a clinic recruiting its own patients for a study. Staff say that anyone who declines will lose usual care. That threat undermines voluntary choice. Signing a form does not remove the pressure. If staff also omit material risks, participants lack information needed for their decision.
Ethics review examines the scientific value of the research as well as participant protection. It asks whether recruitment is fair, privacy is protected, and risks are justified by possible benefits and the value of the knowledge. A person who is vulnerable to pressure needs suitable safeguards. Automatically excluding an entire group can also deny it opportunities to participate and leave its treatment needs understudied.
An attractive hypothesis or a new endpoint cannot repair coercion or missing information. Those defects need changes to the recruitment and consent process before the proposed study proceeds.
Name the event before interpreting its risk ratio
To calculate a risk ratio, define an event and a follow-up period. In each group, divide the number of participants with at least one event by the group total. Then divide treatment risk by control risk. The control risk must be nonzero.
In a hypothetical trial with complete one-year follow-up, 15 of 100 treated participants and 25 of 100 controls have at least one hospital admission. The risks are 0.15 and 0.25. Their ratio is 0.15 / 0.25 = 0.6. The proportion experiencing at least one admission is lower in the treated group. This calculation does not count how many admissions each person had.
A ratio below 1 means less of the named event. Whether that is desirable depends on the event: avoiding a stroke differs from achieving recovery. A ratio of 1 describes equal observed risks; it does not by itself establish treatment equivalence.
A continuous marker change is not a participant risk. It needs a different comparison. For any endpoint, consider uncertainty, missing outcomes and harms before deciding what the result supports.
Explore more
2 · Watch
Take it off screen
Where it sits
Learn first
This opens up
Nothing builds on it yet.
Where this leads
Jobs that lean on this skill. Follow one to see everything it is built on.
8 questions wait behind this lesson, each with its answer explained. Every answer feeds the sky: stars light as they are learned, and dim when it is time to come back.